查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲下一代乳癌診斷和篩檢市場：分析和預測，2023-2032
市場調查報告書
商品編碼
1413711

歐洲下一代乳癌診斷和篩檢市場：分析和預測，2023-2032

Europe Next-Generation Breast Cancer Diagnostic and Screening Market: Analysis and Forecast, 2023-2032
出版日期: | 出版商: BIS Research | 英文 69 Pages | 商品交期: 1-5個工作天內

價格

歐洲下一代乳癌診斷和篩檢市場預計將從 2023 年的 8.4 億美元成長到 2032年終的25.7 億美元，預測期內複合年成長率為 13.20%。

乳癌患者盛行率的增加、乳癌早期診斷意識的提高、對乳癌生物標記的有效篩檢、預後預測、個體化治療以及市場參與企業間聯盟和合作增加的推動。

主要市場統計數據
預測期 2023-2032
2023年評估 8.4億美元
2032年預測 25.7億美元
複合年成長率 13.2%

由於先進醫療技術的早期採用、乳癌高發病率和強大的醫療基礎設施等因素，歐洲下一代乳癌診斷和篩檢市場正在經歷顯著成長。歐洲國家特別重視乳癌意識提升和篩檢，促進將創新生物標記和基因檢測涵蓋診斷。醫療機構、研究機構和行業相關人員之間的合作正在進一步提高診斷的準確性和效率，有助於改善患者的治療結果。這些舉措反映了該地區應對乳癌挑戰的承諾，預計將維持歐洲市場成長並加強乳癌管理。

本報告調查了歐洲下一代乳癌診斷和篩檢市場，並提供了市場概況、市場成長的各種影響因素分析、市場規模趨勢和預測、主要國家的詳細分析、主要企業的分析等。我正在總結。

市場分類

細分 1：按國家/地區

  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 其他

目錄

執行摘要

調查範圍

調查方法

第1章 腫瘤分子診斷市場

  • 概述
  • 癌症類型
  • 科技
  • 市場動態
  • 監管部門核准的產品

第2章 區域

  • 歐洲
    • 主要發現
    • 市場動態
    • 市場規模/預測

第3章市場：競爭基準化分析

  • 活躍的企業生態系統
  • 公司簡介
    • Agendia Inc.
    • CENTOGENE NV
    • F. Hoffmann-La Roche Ltd.
Product Code: BHP1806SS

“The Europe Next-Generation Breast Cancer Diagnostic and Screening Market Expected to Reach $2.57 Billion by 2032.”

Introduction to Europe Next-Generation Breast Cancer Diagnostic and Screening Market

The Europe next-generation breast cancer diagnostic and screening market was valued at $0.84 billion in 2023 and is expected to reach $2.57 billion by the end of 2032, registering a CAGR of 13.20% during the forecast period 2023-2032. The growth in the next-generation breast cancer diagnostic and screening market is expected to be driven by the increase in the prevalence of breast cancer cases, rising awareness regarding early diagnosis of breast cancer, growing focus on breast cancer biomarkers for effective screening, prognosis, and personalized treatment, and increasing partnerships and collaborations amongst market players.

KEY MARKET STATISTICS
Forecast Period2023 - 2032
2023 Evaluation$0.84 Billion
2032 Forecast$2.57 Billion
CAGR13.2%

Market Introduction

The European Next-Generation Breast Cancer Diagnostic and Screening Market is experiencing significant growth driven by factors such as the region's early adoption of advanced medical technologies, a high prevalence of breast cancer, and a strong healthcare infrastructure. European countries prioritize breast cancer awareness and screening, fostering the integration of innovative biomarkers and genetic testing into diagnosis. Collaborations between healthcare institutions, research organizations, and industry players further enhance diagnostic accuracy and efficiency, contributing to improved patient outcomes. These efforts reflect the region's commitment to addressing breast cancer challenges and are expected to sustain market growth and enhance breast cancer management in Europe.

Market Segmentation:

Segmentation 1: by Country

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest-of-Europe

How can this report add value to an organization?

Growth/Marketing Strategy: The Europe next-generation breast cancer diagnostic and screening market has seen major development by key players operating in the market, such as business expansions, partnerships, collaborations, mergers and acquisitions, product launches, and funding activities. Partnerships, alliances, and business expansions accounted for the maximum number of key developments in the Europe next-generation breast cancer diagnostic and screening market, followed by regulatory and legal activities and mergers and acquisitions.

Competitive Strategy: Key players in the Europe next-generation breast cancer diagnostic and screening market analyzed and profiled in the study involve players that offer next-generation breast cancer diagnostic and screening products and services. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, product launches and approvals, and funding scenarios will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

  • Agendia Inc.
  • CENTOGENE N.V.
  • F. Hoffmann-La Roche Ltd.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Oncology Molecular Diagnostic Market

  • 1.1. Overview
  • 1.2. Cancer Type
  • 1.3. Technology
  • 1.4. Market Dynamics
  • 1.5. Regulatory-Approved Products

2. Regions

  • 2.1. Europe
    • 2.1.1. Key Findings
    • 2.1.2. Market Dynamics
      • 2.1.2.1. Impact Analysis
    • 2.1.3. Market Sizing and Forecast
      • 2.1.3.1. Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
        • 2.1.3.1.1. Germany
          • 2.1.3.1.1.1. Market Dynamics
          • 2.1.3.1.1.2. Market Sizing and Forecast
        • 2.1.3.1.2. France
          • 2.1.3.1.2.1. Market Dynamics
          • 2.1.3.1.2.2. Market Sizing and Forecast
        • 2.1.3.1.3. U.K.
          • 2.1.3.1.3.1. Market Dynamics
          • 2.1.3.1.3.2. Market Sizing and Forecast
        • 2.1.3.1.4. Italy
          • 2.1.3.1.4.1. Market Dynamics
          • 2.1.3.1.4.2. Market Sizing and Forecast
        • 2.1.3.1.5. Spain
          • 2.1.3.1.5.1. Market Dynamics
          • 2.1.3.1.5.2. Market Sizing and Forecast
        • 2.1.3.1.6. Rest-of-Europe
          • 2.1.3.1.6.1. Market Dynamics
          • 2.1.3.1.6.2. Market Sizing and Forecast

3. Markets - Competitive Benchmarking

  • 3.1. Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
  • 3.2. Company Profiles
    • 3.2.1. Agendia Inc.
      • 3.2.1.1. Company Overview
      • 3.2.1.2. Role of Agendia Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
      • 3.2.1.3. Recent Developments
      • 3.2.1.4. Analyst Perception
    • 3.2.2. CENTOGENE N.V.
      • 3.2.2.1. Company Overview
      • 3.2.2.2. Role of CENTOGENE N.V. in the Next-Generation Breast Cancer Diagnostic and Screening Market
      • 3.2.2.3. Financials
      • 3.2.2.4. Recent Developments
      • 3.2.2.5. Analyst Perception
    • 3.2.3. F. Hoffmann-La Roche Ltd.
      • 3.2.3.1. Company Overview
      • 3.2.3.2. Role of F. Hoffmann-La Roche Ltd. in the Next-Generation Breast Cancer Diagnostic and Screening Market
      • 3.2.3.3. Financials
      • 3.2.3.4. Recent Developments
      • 3.2.3.5. Analyst Perception

List of Figures

  • Figure 1: Worldwide Breast Cancer Statistics (by Region), 2020
  • Figure 2: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 3: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), $Million, 2022 and 2032
  • Figure 4: Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
  • Figure 5: Next-Generation Breast Cancer Diagnostic and Screening Market, Key Development Analysis, January 2019-April 2023
  • Figure 6: Next-Generation Breast Cancer Diagnostic and Screening Market: Research Methodology
  • Figure 7: Primary Research Methodology
  • Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 9: Top-Down Approach (Segment-Wise Analysis)
  • Figure 10: Oncology Molecular Diagnostic Market, Solid Tumor, $Million, 2022 and 2032
  • Figure 11: Oncology Molecular Diagnostic Market, Hematological Malignancy, $Million, 2022 and 2032
  • Figure 12: Oncology Molecular Diagnostic Market, Market Dynamics
  • Figure 13: Next-Generation Breast Cancer Diagnostic and Screening Market Share (by Region), 2022-2032
  • Figure 14: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
  • Figure 15: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 16: Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
  • Figure 17: Germany Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 18: France Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 19: U.K. Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 20: Italy Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 21: Spain Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 22: Rest-of-Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 23: Agendia Inc.: Product Portfolio
  • Figure 24: CENTOGENE N.V.: Product Portfolio
  • Figure 25: CENTOGENE N.V.: Overall Financials, $Million, 2019-2021
  • Figure 26: CENTOGENE N.V.: Net Revenue (by Segment), $Million, 2019-2021
  • Figure 27: CENTOGENE N.V.: Net Revenue (by Region), $Million, 2019-2021
  • Figure 28: CENTOGENE N.V.: R&D Expenditure, $Million, 2019-2021
  • Figure 29: F. Hoffmann-La Roche Ltd.: Product Portfolio
  • Figure 30: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2020-2022
  • Figure 31: F. Hoffmann-La Roche Ltd.: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 32: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: Key Questions Answered in the Report
  • Table 2: Some of the Regulatory-Approved Oncology Molecular Diagnostic Products/Services for Different Types of Solid Tumors
  • Table 3: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
  • Table 4: Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
  • Table 5: Agendia Inc.: Key Services and Features
  • Table 6: CENTOGENE N.V.: Key Services and Features
  • Table 7: F. Hoffmann-La Roche Ltd.: Key Products and Features